Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription 25.08.2025 1 AJR Am J Roentgenol 2 Am J Gastroenterol 1 Am J Pathol 2 Biochem Biophys Res Commun 1 BMC Cancer 9 BMC Gastroenterol 2 Cancer Res 1 Dig Dis 3 Dig Dis Sci 1 Endoscopy 4 Eur Radiol 5 Gastroenterology 1 Gut 13 Hepatology 1 Indian J Gastroenterol 2 Int J Cancer 1 J Gastroenterol 1 J Gastroenterol Hepatol 6 J Hepatol 1 J Pediatr Surg 5 Lancet 5 N Engl J Med 1 PLoS Genet 5 PLoS One 1 Radiol Imaging Cancer 2 Semin Liver Dis 2 Transplantation

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. CHIU SH, Kesselman A, Delitto DJ, Dhanasekaran R, et al
   Hepatocellular Carcinoma: A Practical Anatomy-Based Guide for Staging and Treatment Planning, From the AJR Special Series on Critical Anatomy.
   AJR Am J Roentgenol. 2025 Aug 20. doi: 10.2214/AJR.25.33389.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

2. PRAKASH JH, Anirvan P, Gupta S, Chouhan MI, et al
   Diagnostic Accuracy of Spleen-dedicated 100 Hz Transient Elastography to Predict High-risk Esophageal Varices.
   Am J Gastroenterol. 2025 Aug 22. doi: 10.14309/ajg.0000000000003741.
   PubMed         Abstract available
   
   
3. JEFFREY AW, Majumdar A, Jeffrey G, Calzadilla-Bertot L, et al
   The Portal Hypertension Decompensation Score - A Validated Predictive Model of Liver Decompensation Related to Portal Hypertension.
   Am J Gastroenterol. 2025 Aug 22. doi: 10.14309/ajg.0000000000003744.
   PubMed         Abstract available
   
   

   
   Am J Pathol

4. WANG Z, Xu Q, Wang M, Xiao Q, et al
   Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients and Mice with Wilson Disease.
   Am J Pathol. 2025;195:1600-1618.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

5. WANG H, Lu J, Chen K, Ma B, et al
   Efficient derivation of immortalized, isogenic cell lines from genetically defined murine hepatoblastomas.
   Biochem Biophys Res Commun. 2025;780:152478.
   PubMed         Abstract available
   
   
6. ZHONG B, Zhu Q, Wei P, Wang X, et al
   TMAO regulates OTUB1-mediated SLC7A11 stability to promote NAFLD progression.
   Biochem Biophys Res Commun. 2025;778:152352.
   PubMed         Abstract available
   
   

   
   BMC Cancer

7. LEE CH, Lee YC, Seo SY, You GR, et al
   Pre- and postoperative predictors of extrahepatic recurrence after curative resection for hepatocellular carcinoma.
   BMC Cancer. 2025;25:1368.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

8. HUANG WT, Cheng DL, Yin L, Dong L, et al
   A GLIM-defined malnutrition-based model for predicting prognosis of cirrhotic patients with portal hypertension following TIPS procedure.
   BMC Gastroenterol. 2025;25:586.
   PubMed         Abstract available
   
   
9. WANG S
   Association of alpha-1 acid glycoprotein with hepatic steatosis and liver fibrosis among women: a population-based study.
   BMC Gastroenterol. 2025;25:587.
   PubMed         Abstract available
   
   
10. DONG C, Liu SX, Zou B, Shu SN, et al
    Mechanism of NOTCH2 in promoting intrahepatic bile duct development.
    BMC Gastroenterol. 2025;25:612.
    PubMed         Abstract available
    
    
11. YANG H, Zhang B, Yu C, Zhu X, et al
    Construction of a predictive model for concurrent infection in liver failure patients based on prognostic nutritional index and inflammatory cytokine analysis.
    BMC Gastroenterol. 2025;25:598.
    PubMed         Abstract available
    
    
12. ZHANG X, Ai Z
    Efficacy and safety of reduced thromboprophylaxis with low molecular weight heparin for hepatocellular carcinoma after conversion therapy.
    BMC Gastroenterol. 2025;25:606.
    PubMed         Abstract available
    
    
13. LI Q, Ruan Y, Zhu Y, Cai Y, et al
    An updated systematic review and meta-analysis: correlation between circulating plasminogen activator inhibitor-1 levels and metabolic dysfunction-associated steatotic liver disease.
    BMC Gastroenterol. 2025;25:604.
    PubMed         Abstract available
    
    
14. YUAN T, Jia G, Cao W, Chen H, et al
    The prognostic value of indoleamine 2,3-dioxygenase in colorectal cancer: a systematic review and meta-analysis.
    BMC Gastroenterol. 2025;25:603.
    PubMed         Abstract available
    
    
15. DINCER S, Ulger Y, Delik A
    Mucosal microbiota signatures reveal diagnostic insights in chronic liver disease.
    BMC Gastroenterol. 2025;25:607.
    PubMed         Abstract available
    
    
16. ZOU Y, Dai Y, Chen H, Li Z, et al
    MAFLD outperforms NAFLD in identifying metabolic dysfunction in U.S. adolescents: a NHANES 2017-2020 analysis.
    BMC Gastroenterol. 2025;25:617.
    PubMed         Abstract available
    
    

    
    Cancer Res

17. GONG X, Ogino N, Leite MF, Zhang D, et al
    Adaptation to Volumetric Compression Drives an Apoptosis-Resistant and Invasive Phenotype in Liver Cancer.
    Cancer Res. 2025;85:3156-3175.
    PubMed         Abstract available
    
    
18. LIU Y, Liu FS, Liu J, Cairang D, et al
    The Acetyltransferase ARD1 Induces Glutathione Synthesis to Facilitate Ferroptosis Evasion in Hepatocellular Carcinoma.
    Cancer Res. 2025 Aug 21. doi: 10.1158/0008-5472.CAN-24-4015.
    PubMed         Abstract available
    
    

    
    Dig Dis

19. LI W, Tian Y, Jing L
    Diagnostic value and prognostic effect of miR-7-5p in cirrhosis.
    Dig Dis. 2025 Aug 13:1-17. doi: 10.1159/000547157.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

20. FAIZ M, Usman M, Irshad NUN
    Clinical Insights on "Applying Metabolomics and Aptamer-Based Proteomics to Determine Pathophysiologic Differences in Decompensated Cirrhosis Patients Hospitalized with Acute Kidney Injury".
    Dig Dis Sci. 2025 Aug 19. doi: 10.1007/s10620-025-09329.
    PubMed        
    
    
21. LIU Y, Liu Q, Huang T, Zhang S, et al
    cPDS Promotes Cell Apoptosis by Reducing the Translational Efficiency of BIRC3 mRNA in HCC.
    Dig Dis Sci. 2025;70:2706-2718.
    PubMed         Abstract available
    
    
22. ABREU ES, Reginato PH, Pitanga JFJ, Borges PN, et al
    Obeticholic Acid vs Fibrates as Second-Line Therapy for Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
    Dig Dis Sci. 2025 Apr 19. doi: 10.1007/s10620-025-09044.
    PubMed         Abstract available
    
    

    
    Endoscopy

23. KODA H, Hara K, Okuno N, Haba S, et al
    A novel technique of B2-B3 single-puncture bridging through liver parenchyma enabling endoscopic ultrasound-guided hepaticogastrostomy for rescue drainage.
    Endoscopy. 2025;57.
    PubMed        
    
    

    
    Eur Radiol

24. MINAMIGUCHI K, Maki H, Haddad A, Cortes AC, et al
    Synthetic tumor extracellular volume as a predictive biomarker for colorectal liver metastasis patients prior to curative hepatectomy.
    Eur Radiol. 2025;35:5348-5359.
    PubMed         Abstract available
    
    
25. CHOI SJ, Kim HY, Lee SJ, Kim SY, et al
    Value of enhancing capsule for diagnosing hepatocellular carcinoma on MRI: implications for simplifying LI-RADS.
    Eur Radiol. 2025 Aug 22. doi: 10.1007/s00330-025-11938.
    PubMed         Abstract available
    
    
26. MA W, Huang X, Feng Z, Tan W, et al
    A novel multi-parameter MRI-based model for identification of high-risk metabolic dysfunction-associated steatohepatitis.
    Eur Radiol. 2025 Aug 21. doi: 10.1007/s00330-025-11944.
    PubMed         Abstract available
    
    
27. LIU Z, Chen H, Yang S, Zhang R, et al
    Preoperative prediction model of microvascular invasion in intrahepatic cholangiocarcinoma patients based on CT radiomics can assist clinical surgical decision-making: a multicenter study.
    Eur Radiol. 2025 Aug 14. doi: 10.1007/s00330-025-11900.
    PubMed         Abstract available
    
    

    
    Gastroenterology

28. LOU TW, Ren TY, Fan JG
    An Unusual Cause of Hypolipidemia With Cirrhosis in a Father-Son Pair.
    Gastroenterology. 2025 Aug 21:S0016-5085(25)05901.
    PubMed        
    
    
29. JIANG C, Li Z, Seok S, Li P, et al
    Systemic Identification of Functionally Conserved Long Noncoding RNA Metabolic Regulators in Human and Mouse Livers.
    Gastroenterology. 2025;169:676-690.
    PubMed         Abstract available
    
    
30. ROHM TV, Dos Reis FCG, Cunha E Rocha K, Isaac R, et al
    Adipose Tissue Macrophages in Metabolic Dysfunction-Associated Steatohepatitis Secrete Extracellular Vesicles That Activate Liver Fibrosis in Obese Male Mice.
    Gastroenterology. 2025;169:691-704.
    PubMed         Abstract available
    
    
31. SINGAL AG, Salem R, Pinato DJ, Pillai A, et al
    Advances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma.
    Gastroenterology. 2025;169:585-599.
    PubMed         Abstract available
    
    
32. SPANN A, Strauss AT, Davis SE, Bhat M, et al
    The Role of Artificial Intelligence in Chronic Liver Diseases and Liver Transplantation.
    Gastroenterology. 2025;169:456-470.
    PubMed         Abstract available
    
    

    
    Gut

33. YUAN Y, Li J, Rao D, Lu X, et al
    ISG15 deficiency in hepatic stellate cells promotes TGFbeta2-induced liver fibrosis by counteracting CREB1 ISGylation.
    Gut. 2025 Aug 17:gutjnl-2025-335327. doi: 10.1136/gutjnl-2025-335327.
    PubMed         Abstract available
    
    

    
    Hepatology

34. DING J, She HY, Cheng Y, Sun HY, et al
    A novel mechanism involving USP53-regulated BSEP trafficking underlies low-GGT intrahepatic cholestasis.
    Hepatology. 2025 Aug 19. doi: 10.1097/HEP.0000000000001501.
    PubMed         Abstract available
    
    
35. WILECHANSKY RM
    Surging sludge: Intrahepatic cholangiocarcinoma mortality on the rise worldwide.
    Hepatology. 2025;82:543-544.
    PubMed        
    
    
36. ERICKSON H
    Hepatic stellate cells and macrophages: Key players in HCC immune suppression.
    Hepatology. 2025;82:545-546.
    PubMed        
    
    
37. FACCIOLI LAP, Sun Y, Animasahun O, Motomura T, et al
    Human-induced pluripotent stem cell-based hepatic modeling of lipid metabolism-associated TM6SF2-E167K variant.
    Hepatology. 2025;82:638-654.
    PubMed         Abstract available
    
    
38. ANANIA FA, Hager R, Higgins K, Makar GA, et al
    Non-Invasive Tests: Establishing efficacy for metabolic dysfunction associated steatohepatitis beyond the biopsy-current perspectives from the division of hepatology and nutrition, US Food and Drug Administration.
    Hepatology. 2025 Aug 26. doi: 10.1097/HEP.0000000000001509.
    PubMed         Abstract available
    
    
39. HILSCHER MB
    The pressure is on: Elucidating hemodynamic profiles associated with esophageal varices in the Fontan circulation.
    Hepatology. 2025 Aug 26. doi: 10.1097/HEP.0000000000001510.
    PubMed        
    
    
40. SIDDIQUI MS, Muthiah M, Satapathy SK, Patidar K, et al
    Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation.
    Hepatology. 2023 Dec 13. doi: 10.1097/HEP.0000000000000720.
    PubMed         Abstract available
    
    
41. PANG Z, Zhang H, Zheng S, Yang X, et al
    HNF4alpha-CDKL3 axis restricts MASLD progression by targeting FoxO1 via noncanonical phosphorylation.
    Hepatology. 2025;82:702-721.
    PubMed         Abstract available
    
    
42. SINGAL AG, Quirk L, Boike J, Chernyak V, et al
    Value of HCC surveillance in a landscape of emerging surveillance options: Perspectives of a multi-stakeholder modified Delphi panel.
    Hepatology. 2025;82:794-809.
    PubMed         Abstract available
    
    
43. ZHOU KQ, Zhong YC, Song MF, Sun YF, et al
    Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution.
    Hepatology. 2025;82:566-581.
    PubMed         Abstract available
    
    
44. YANG Y, Ni Q, Li H, Sun J, et al
    Genomic and the tumor microenvironment heterogeneity in multifocal hepatocellular carcinoma.
    Hepatology. 2025;82:582-598.
    PubMed         Abstract available
    
    
45. LI W, Chi Y, Xiao X, Li J, et al
    Plasma FSTL-1 as a noninvasive diagnostic biomarker for patients with advanced liver fibrosis.
    Hepatology. 2025;82:669-682.
    PubMed         Abstract available
    
    
46. JEONG JM, Choi SE, Shim YR, Kim HH, et al
    CX3CR1+ macrophages interact with HSCs to promote HCC through CD8+ T-cell suppression.
    Hepatology. 2025;82:655-668.
    PubMed         Abstract available
    
    

    
    Indian J Gastroenterol

47. KULKARNI AV, Rughwani H, Reddy DN
    Assessing portal hypertension and its impact on carbon emissions.
    Indian J Gastroenterol. 2025 Aug 15. doi: 10.1007/s12664-025-01847.
    PubMed        
    
    

    
    Int J Cancer

48. GUERRERO JJG, Encarnacion PC, Del Rosario MAS, Ora MAS, et al
    Genetic variants underlying precancerous conditions of hepatocellular carcinoma.
    Int J Cancer. 2025 Aug 20. doi: 10.1002/ijc.70092.
    PubMed         Abstract available
    
    
49. ZHAO L, Cheng J, Zheng Y, Wu J, et al
    Targeting aerobic glycolysis combats tyrosine kinase inhibitor resistance of hepatocellular carcinoma.
    Int J Cancer. 2025 Aug 16. doi: 10.1002/ijc.70091.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

50. OHAMA H, Hiraoka A, Tada T, Hirooka M, et al
    Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma.
    J Gastroenterol. 2025 Aug 20. doi: 10.1007/s00535-025-02290.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

51. KARATAYLI SC, Weber SN, Hall RA, Hohl M, et al
    Hepatic Inflammation and Liver Injury in a Model of Bacterial Infection Triggered Acute-on-Chronic Liver Injury.
    J Gastroenterol Hepatol. 2025 Aug 17. doi: 10.1111/jgh.70055.
    PubMed         Abstract available
    
    

    
    J Hepatol

52. NEUSCHWANDER-TETRI BA, Akbary K, Carpenter DH, Noureddin M, et al
    The emerging role of second harmonic generation/two photon excitation for precision digital analysis of liver fibrosis in MASH clinical trials.
    J Hepatol. 2025;83:790-799.
    PubMed         Abstract available
    
    
53. ISSA G, Shang Y, Strandberg R, Hagstrom H, et al
    Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden.
    J Hepatol. 2025;83:643-651.
    PubMed         Abstract available
    
    
54. LARSON EL, Ellias SD, Blezek DJ, Klug J, et al
    Simultaneous liver transplant and sleeve gastrectomy provides durable weight loss, improves metabolic syndrome and reduces allograft steatosis.
    J Hepatol. 2025 Mar 13:S0168-8278(25)00139-4. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available
    
    
55. ROMERO-CRISTOBAL M
    Cirrhosis recompensation: what it is and what it ought to be - insights from the philosophy of science.
    J Hepatol. 2025 Aug 20:S0168-8278(25)02449-3. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
56. RIDOLA L, Riggio O
    Rifaximin and Survival in Cirrhosis: An Unmet Clinical Promise.
    J Hepatol. 2025 Aug 20:S0168-8278(25)02446-8. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
57. TRAMPERT DC
    From parts to portal: Recapitulating hepatobiliary microarchitecture using multicellular organoids.
    J Hepatol. 2025 Aug 20:S0168-8278(25)02346-3. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    

    
    J Pediatr Surg

58. SON TN, Son HD, Mai DV
    Hepatic ductoplasty to widen the hepaticojejunostomy in the single-site laparoscopic resection of choledochal cyst in children.
    J Pediatr Surg. 2025 Aug 13:162554. doi: 10.1016/j.jpedsurg.2025.162554.
    PubMed         Abstract available
    
    

    
    Lancet

59. SHERRY AD, Dudzinski SO, Ludmir EB
    Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial.
    Lancet. 2025;406:693-694.
    PubMed        
    
    
60. ONDER AH
    Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial.
    Lancet. 2025;406:693.
    PubMed        
    
    
61. KUDO M, Ren Z, Finn RS, Llovet JM, et al
    Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial - Authors' reply.
    Lancet. 2025;406:694.
    PubMed        
    
    
62. NOUREDDIN M, Frias JP, Neff GW, Lucas KJ, et al
    Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
    Lancet. 2025;406:719-730.
    PubMed         Abstract available
    
    
63. LOOMBA R, Morgan E, Yousefi K, Li D, et al
    Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2025;406:821-831.
    PubMed         Abstract available
    
    

    
    N Engl J Med

64. SANYAL AJ, Newsome PN
    Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. Reply.
    N Engl J Med. 2025;393:827-828.
    PubMed        
    
    
65. SU CY, Hasebe M
    Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
    N Engl J Med. 2025;393:827.
    PubMed        
    
    
66. RIVERA-ESTEBAN J, Valverde-Salazar V, Calleja JL
    Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
    N Engl J Med. 2025;393:827.
    PubMed        
    
    
67. LAVENDER J, Bollipo S, Talley N
    Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
    N Engl J Med. 2025;393:826.
    PubMed        
    
    
68. LUO S, Liu H, Jin W
    Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
    N Engl J Med. 2025;393:826.
    PubMed        
    
    

    
    PLoS Genet

69. SAWYER G, Sallis H, Munafo M, Mahedy L, et al
    Understanding the alcohol harm paradox: A multivariable mendelian randomization approach.
    PLoS Genet. 2025;21:e1011824.
    PubMed         Abstract available
    
    

    
    PLoS One

70. QIN H, Chen R, Xie Y, Liu H, et al
    Kummerowia striata extract protects paracetamol-induced liver injury by modulating the S1P/Nrf2/Keap1 pathway.
    PLoS One. 2025;20:e0329837.
    PubMed         Abstract available
    
    
71. ABLAYEVA A, Syssoyev D, Akhmedullin R, Beyembetova A, et al
    Epidemiology of liver cancer in Kazakhstan: data from the Unified National Electronic Health System, 2014-2023.
    PLoS One. 2025;20:e0330423.
    PubMed         Abstract available
    
    
72. LIU Y, Shao Y, Zhu X, Shen Z, et al
    Mitochondrial proteins: Potential pathophysiological mechanisms of malignant progression in HCC.
    PLoS One. 2025;20:e0329209.
    PubMed         Abstract available
    
    
73. MAO Y, Du J, Li B, Wang J, et al
    Global burden of NAFLD 1990-2021 and projections to 2035: Results from the Global Burden of Disease study 2021.
    PLoS One. 2025;20:e0330504.
    PubMed         Abstract available
    
    
74. MULLER L, Kloeckner R, Heim L, Moos M, et al
    Bone mineral density predicts survival in patients with hepatocellular carcinoma and portal vein tumor thrombosis.
    PLoS One. 2025;20:e0330336.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

75. ARRIVE L, Djelouah M
    Refining Prognosis in Intrahepatic Cholangiocarcinoma: The Expanding Role of Imaging.
    Radiol Imaging Cancer. 2025;7:e250383.
    PubMed        
    
    

    
    Semin Liver Dis

76. HASSAN A, Tapper E
    Patient-centered treatment of cirrhosis.
    Semin Liver Dis. 2025 Aug 18. doi: 10.1055/a-2684-6289.
    PubMed         Abstract available
    
    
77. BALOGUN O, Nejak-Bowen K
    Animal Models of Porphyria with Hepatic Involvement.
    Semin Liver Dis. 2025 Aug 21. doi: 10.1055/a-2677-6806.
    PubMed         Abstract available
    
    

    
    Transplantation

78. YANG M, Wang J, Li C, Yang Z, et al
    Serine Glycine Restriction Aggravates Hepatic Ischemia-reperfusion Injury.
    Transplantation. 2025 Aug 22. doi: 10.1097/TP.0000000000005487.
    PubMed         Abstract available
    
    
79. YAKUBU I, Spengler J, Taylor P, LaPorte M, et al
    Impact of Glucagon-like Peptide-1 Receptor Agonists on Metabolic Health in Liver Transplant Recipients.
    Transplantation. 2025 Mar 25. doi: 10.1097/TP.0000000000005361.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.